CERE - Cerevel Therapeutics Holdings, Inc.
After hours:
| Previous Close | 32.57 |
| Open | 32.64 |
| Bid | 31.79 x 1100 |
| Ask | 33.67 x 800 |
| Day's Range | 32.51 - 33.46 |
| 52 Week Range | 22.10 - 41.46 |
| Volume | |
| Avg. Volume | 601,506 |
| Market Cap | 5.238B |
| Beta (5Y Monthly) | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer
Susan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to Cerevel Dr. Altschuller to become CFO effective May 15, 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Susan Altschuller, Ph.D. as chief financial officer (CFO)
- GlobeNewswire
Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results
Ron Renaud to succeed Tony Coles, M.D. as CEO, effective June 12, 2023; Dr. Coles will continue as chairperson of the board Mr. Renaud brings more than 25 years of biotechnology leadership to Cerevel, including two prior CEO roles and strong financial and operational experience Emraclidine Phase 2 schizophrenia data readout on track for 1H 2024 Darigabat Phase 2 epilepsy data readout expected mid-year 2024; panic disorder Phase 2 trial expected to initiate in Q2 2023 Cash, cash equivalents, and
- GlobeNewswire
Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 2023 BofA Securities Health Care Conference. Date: Wednesday, May 10th Format: Presentation at 10:00 am PT (1:00 pm ET) The live webcast of the presentation can be accessed on the investor relations section of
- GlobeNewswire
Cerevel Therapeutics to Report First Quarter 2023 Financial Results and Business Updates on Wednesday, May 3, 2023
CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2023 financial results and business updates on Wednesday, May 3, 2023, before the U.S. financial markets open. Management will host a conference call to discuss first quarter financial results and business updates on Wednesday, May 3 at 8:00 a.m. ET. To access the call, p
- GlobeNewswire
Cerevel Therapeutics to Present at the Stifel 2023 CNS Days
CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will participate in a fireside chat at the Stifel Virtual 2023 CNS Days on Wednesday, March 29, 2023 at 10:30 am ET. The live webcast of the presentation can be accessed on the investor relations section of the Cerevel Therapeutics websi
- GlobeNewswire
Cerevel Therapeutics to Present at the 43rd Annual Cowen Health Care Conference
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 43rd Annual Cowen Health Care Conference. Date: Monday, March 6, 2023 Format: Presentation at 9:10 a.m. EST The live webcast of the presentation can be accessed on the investor relations section of the Cereve
- GlobeNewswire
Cerevel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Emraclidine Phase 1 healthy elderly volunteer trial enrollment underway to support development in Alzheimer’s disease psychosis Emraclidine Phase 2 schizophrenia data readout remains on track for 1H 2024 Clinical trial timeline updates provided for additional lead programs Cash, cash equivalents, and marketable securities of $950 million as of December 31, 2022, expected to support operations into 2025 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cere
- GlobeNewswire
Cerevel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates on Wednesday, February 22, 2023
CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter and full year 2022 financial results and business updates on Wednesday, February 22, 2023, before the U.S. financial markets open. Management will host a conference call to discuss fourth quarter and full year 2022 financial results and business updates on Wednesday, Febr
- GlobeNewswire
Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update
Initiated Phase 1 healthy volunteer trial to support development of emraclidine in Alzheimer’s disease psychosis in Q4 2022; second potential indication as a once-daily treatment Phase 2 proof-of-concept darigabat panic disorder trial to be initiated in Q2 2023 Multiple data readouts and cash runway into 2025 to support advancement of diverse pipeline of novel neuroscience drug candidates Cerevel presentation to take place on January 10 at 8:15 a.m. PT/11:15 a.m. ET CAMBRIDGE, Mass., Jan. 09, 20
- GlobeNewswire
Cerevel Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference. Dr. Coles will be joined by additional members of the executive team for the question-and-answer portion of the presentation. Date: Tuesday, January 10, 2023 Form
- GlobeNewswire
Cerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring Trial
Data provide clear evidence that emraclidine does not induce an increase in blood pressure with chronic dosing in people living with schizophrenia Emraclidine demonstrated a mean change from baseline in 24-hour ambulatory systolic blood pressure at week eight of -2.7 mmHg for 10 mg QD and -0.4 mmHg for 30 mg QD Trial ruled out a 3 mmHg or greater increase in 24-hour mean systolic blood pressure for both doses of emraclidine based on the upper bound of the 95% confidence interval, per FDA guidanc
- GlobeNewswire
Cerevel Therapeutics Announces Publication in The Lancet of Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia
Emraclidine is being developed as a potential once-daily treatment for schizophrenia without the need for titration Data show clinically meaningful and statistically significant improvement with emraclidine in PANSS total score at six weeks and was overall well-tolerated compared with placebo Results demonstrate selective targeting of the M4 muscarinic receptor subtype as a potential novel treatment approach for schizophrenia Comprehensive Phase 2 development program in schizophrenia currently u
- GlobeNewswire
Cerevel Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in three upcoming investor conferences. Event: Guggenheim Healthcare Talks 4th Annual Immunology & Neurology DayDate: Tuesday, November 15, 2022Format: One-on-one meetings Event: Stifel 2022 Healthcare ConferenceDate: Wednesday, November 16, 2022Format:
- GlobeNewswire
Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates
Completed $599 million dual convertible debt and equity financing to advance a robust neuroscience therapeutics pipeline Initiated EMPOWER-3, a 52-week open-label extension trial of emraclidine in people with schizophrenia Received FDA Fast Track designation for emraclidine in Alzheimer’s disease psychosis; Phase 1 trial in healthy, elderly volunteers to be initiated by year-end Cash, cash equivalents and marketable securities of $1,030 million as of September 30, 2022, expected to support opera
- GlobeNewswire
Cerevel Therapeutics to Report Third Quarter 2022 Financial Results and Pipeline Update on Tuesday, November 8, 2022
CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2022 financial results on Tuesday, November 8, 2022, before the U.S. financial markets open. Management will host a conference call to discuss third quarter 2022 financial results and recent business updates on Tuesday, November 8, 2022, at 8:00 a.m. ET. To access the call
- GlobeNewswire
Cerevel Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022. Chairperson and Chief Executive Officer Tony Coles, M.D., will participate in a fireside chat at 9:20AM ET. The live webcast of the fireside chat can be access
- GlobeNewswire
Cerevel Therapeutics Announces Pricing of $254 Million Public Offering of Common Stock and Concurrent $300 Million Private Offering of Convertible Senior Notes
CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 7,250,000 shares of its common stock at a public offering price of $35.00 per share, or approximately $253.8 million of shares of its common stock. In addition, Cerevel granted the u
- GlobeNewswire
Cerevel Therapeutics Announces Pricing of $300 Million Private Offering of Convertible Senior Notes and Concurrent $254 Million Public Offering of Common Stock
CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced private offering of $300.0 million aggregate principal amount of 2.50% convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under
- GlobeNewswire
Cerevel Therapeutics Announces Proposed Private Offering of Convertible Senior Notes
CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has commenced a private offering of $250.0 million aggregate principal amount of convertible senior notes due 2027 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of
- GlobeNewswire
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. In connection with this offering, Cerevel expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of
- GlobeNewswire
Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
Initiated two parallel, adequately-powered Phase 2 trials of emraclidine in schizophrenia with data expected 1H 2024 Phase 1 trial of emraclidine to be initiated by year-end to support future development in Alzheimer’s disease psychosis Panic disorder selected as second indication for darigabat, planning underway for Phase 2 proof-of-concept Cash, cash equivalents and marketable securities of $531M as of June 30, 2022, expected to support operations into 2024 Conference call today at 8:00 a.m. E
- GlobeNewswire
Cerevel Therapeutics to Report Second Quarter 2022 Financial Results and Pipeline Update on Monday, August 1, 2022
CAMBRIDGE, Mass., July 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2022 financial results on Monday, August 1, 2022, before the U.S. financial markets open. Management will host a conference call to discuss second quarter 2022 financial results and recent business updates on Monday, August 1, 2022 at 8:00 a.m. ET. To access the call, ple
- GlobeNewswire
Cerevel Therapeutics Announces Updates to its Board of Directors
CAMBRIDGE, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has appointed Suneet Varma to serve as a member of its board of directors. Mr. Varma succeeds Morris Birnbaum, M.D., Ph.D., who announced that he is retiring from his role as Senior Vice President and Chief Scientific Officer of Internal Medicine at Pfizer Inc., and will therefore be stepping
